3 results about "Neo epitope" patented technology

This invention belongs to the field of biomedical technology, specifically disclosing the application of a CTL epitope peptide derived from the neoantigen ESR1 or its encoded nucleic acid in the preparation of a drug for treating tumors. Through analysis of the COSMIC database, epitope prediction, and in vitro and in vivo immunomodulatory activity experiments, this invention identified an HLA-A2-restricted CTL epitope peptide derived from the neoantigen ESR1. This mutant epitope peptide originates from a high-frequency mutation of ESR1 and can effectively stimulate and induce the production of neotope-specific cytotoxic T lymphocytes, specifically distinguishing between wild-type and mutant sequences, and killing tumor cells expressing the mutant epitope, exhibiting good anti-tumor effects. The resulting drug for treating tumors may contain the CTL epitope peptide derived from the neoantigen ESR1 or its encoded nucleic acid, or may contain a T-cell receptor, chimeric antigen receptor, or its encoded nucleic acid that specifically recognizes the mutant epitope peptide, demonstrating good therapeutic potential and clinical application prospects.

The application provides preparation and application of a diagnostic monoclonal antibody for a new epitope of human neutrophil lipocalin (HNL). Two new HNL protein conformation epitopes and one new HNL linear epitope are designed and provided, and an anti-HNL antibody with higher binding affinity and better binding specificity is screened to combine the new epitopes. The anti-HNL antibody of the application can be used for preparation of an HNL detection reagent and kit, and has higher sensitivity and specificity when used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and viral infection.

This invention discloses an injury-related endogenous polypeptide and its applications. The invention employs a "single-model initial screening – multi-model cross-validation" strategy, using an acute lung injury (ALI) model as the screening set and partial hepatectomy (PHx) and cerebral ischemia-reperfusion injury (tMCAO) models as the validation set. Combined with liquid chromatography-tandem mass spectrometry (LC-MS / MS) technology, a group of serum endogenous polypeptides was screened. These polypeptides are novel epitope fragments generated by specific enzymatic digestion of precursor proteins such as fibrinogen α-chain and hemoglobin α / β subunits in the tissue injury microenvironment. Their expression levels are extremely low in healthy serum but exhibit explosive upregulation in injured states. Experiments have confirmed that this group of polypeptides shows significant responses in acute lung injury, liver injury, and cerebral ischemia-reperfusion injury models, and can serve as broad-spectrum biomarkers for multi-tissue injury, providing a novel detection target for the early diagnosis of multi-tissue injury in acute and critical clinical settings.